It can be used as an analgesic for moderate to severe pain in non-ambulant patients (the latter being because of its strong sedative effects).<unk>  is also used at lower doses for the treatment of nausea and insomnia.<unk>  is frequently prescribed and valued worldwide in palliative care medicine for its multimodal action, to treat intractable nausea or vomiting, and for severe delirium/agitation in the last days of life. Palliative care physicians will commonly prescribe it orally or via subcutaneous syringe drivers in combination with opioid analgesics such as hydromorphone.<unk>  is used for the treatment of psychosis, particularly those of schizophrenia, and manic phases of bipolar disorder. It should only be used with caution in the treatment of agitated depressions, as it can cause akathisia as a side effect, which could worsen the agitation. A 2010 systematic review compared the efficacy of<unk>  with atypical antipsychotic drugs: +<unk>  versus atypical antipsychotic drugs for schizophrenia Summary Data are few and not high quality making it impossible to be confident about the effects for schizophrenia. Outcome Findings in words Findings in numbers Quality of evidence Global state Not much improved (CGI)Follow-up: short-term<unk>  may increase the risk of not seeing an improvement when compared with atypical antipsychotic drugs, but, at present there are only very limited data supporting this finding. RR 2.33 (1.11 to 4.89) Very low Mental state Any response (Follow-up: short-term At present it is not possible to be confident about the difference between people given<unk>  and those receiving atypical antipsychotic drugs. There is very limited data to support this finding. RR 2.5 (0.93 to 6.72) Very low Adverse events Constipation<unk>  may slightly reduce the risk of constipation but there is no clear difference between people given<unk>  and those receiving atypical antipsychotics. These findings are based on data of low quality. RR 0.45 (0.07 to 2.94) Low Dizziness<unk>  may increase the chance of experiencing dizziness when compared with atypical antipsychotic drugs. Data are based on low quality evidence. RR 2.59 (1.23 to 5.46) Low Drowsiness There is no clear difference for the outcome of 'drowsiness' between people given<unk>  and those receiving atypical antipsychotic drugs. These findings are based on data of low quality. RR 0.62 (0.29 to 1.32) Low Dry mouth Dry mouth is no more or less common with<unk>  compared with those receiving atypical antipsychotic drugs. These findings are based on data of low quality. RR 0.93 (0.45 to 1.95) Low Extrapyramidal symptoms - Needing antiparkinsonian medication<unk>  may reduce the risk of movement disorders but, with current data, there is no clear difference between people given<unk>  and those receiving atypical antipsychotic drugs. These findings are based on data of very limited quality. RR 0.6 (0.16 to 2.2) Very low
Levomepromazine
Acetomepregenol
Bethanechol
Dextropropoxyphene
Triflupromazine
Dexmedetomidine
Avacopan
Metaxalone